Restitution-forskning
Peptider studeret i modeller for vævsreparation og inflammation. Nedenfor er den publicerede litteratur for hver forbindelse inden for dette område — 85 studier i alt, 39 af dem publiceret siden 2023, alle linket til deres kildepost.
- RestitutionTidlig klinisk
ARA290
ARA290 (cibinetide) is an 11-amino-acid non-erythropoietic peptide engineered from the helix B domain of erythropoietin, designed to activate the innate repair receptor (an EPO receptor/CD131 heteromer) without stimulating erythropoiesis. Of the compounds in this category it has the most developed human evidence: multiple completed randomised placebo-controlled phase 2 trials in sarcoidosis-associated small fibre neuropathy, type 2 diabetes with painful neuropathy, and diabetic macular edema. Results have generally shown improvement in patient-reported neuropathic symptoms and in corneal nerve fibre measures, but no regulatory approval has followed and no phase 3 programme has reported.
- Studier
- 17
- Siden 2023
- 7
- Nyeste
- 2026
- RestitutionTidlig klinisk
BPC-157
BPC-157 is a synthetic pentadecapeptide derived from a fragment of a protein found in gastric juice. The evidence base is overwhelmingly preclinical: several hundred rodent studies report accelerated healing of tendon, ligament, muscle and gastrointestinal tissue, with mechanisms attributed to angiogenesis, VEGFR2 signalling and nitric oxide system modulation. Peer-reviewed human data are limited to a small number of uncontrolled pilot studies and retrospective case series from a single private clinic, plus one ex vivo study on surgically discarded human arterial tissue; a 2026 preprint, not peer reviewed, describes health records of 1,039 people with documented BPC-157 use. No completed randomised controlled trial and no approved formulation exist, and 2025-2026 systematic reviews in orthopaedic journals explicitly characterise the human evidence as insufficient.
- Studier
- 18
- Siden 2023
- 10
- Nyeste
- 2026
- RestitutionKun præklinisk
KPV
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13). Its evidence base is entirely preclinical and is concentrated in gut inflammation, where oral or rectal delivery via the PepT1 di/tripeptide transporter reduces colitis severity in rodent models, and in topical or barrier-protective applications in keratinocytes. A substantial share of the recent literature is formulation science (nanoparticles, hydrogels, microneedles) rather than new pharmacology. There are no human trials of KPV for any indication.
- Studier
- 17
- Siden 2023
- 6
- Nyeste
- 2026
- RestitutionTidlig klinisk
TB-500
Thymosin beta-4 (Tb4) is a 43-amino-acid endogenous actin-sequestering peptide with a large preclinical literature on tissue repair, angiogenesis, anti-fibrotic activity and inflammation resolution. TB-500 is the synthetic Ac-LKKTETQ fragment marketed as a Tb4 analogue; almost all published biology concerns full-length Tb4 rather than the fragment, and the two are frequently conflated. Human evidence is more developed than for most peptides in this category, including completed phase 1 safety studies, a phase 2 dry eye trial and a 2025 study reporting outcomes in both mice and STEMI patients, but no product is approved for musculoskeletal recovery.
- Studier
- 24
- Siden 2023
- 10
- Nyeste
- 2026
- RestitutionKun præklinisk
TB-500 + BPC-157
One published study has directly tested BPC-157 and TB-500 together against each agent alone, and it found no additive benefit. Beyond that single rat Achilles tendon experiment and one retrospective human chart review in which some knee-pain patients received BPC 157 combined with thymosin beta-4, there is no peer-reviewed evidence for the combination. All other support is component-level: the two peptides have separate preclinical literatures that have been reviewed together in sports-medicine journals, but no synergy has been demonstrated in any model.
- Studier
- 9
- Siden 2023
- 6
- Nyeste
- 2026
Senest publiceret forskning
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice
Neurobiol Dis · male db/db mice and db/m lean controls on a touchscreen operant platform (pairwise visual discrimination and reversal learning), with glucose and insulin tolerance testing, flow cytometry and RNA-seq; ARA 290 treatment arm
PubMed · 41933665Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
Mo Med · narrative clinical review of unregulated injectable peptides
PubMed · 42757290Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
Jt Dis Relat Surg · rat Achilles tendon transection and repair; 32 male Sprague-Dawley rats, 4 groups of 8 (control, BPC-157 10 ug/kg/day, TB-500 60 ug/kg/day, combination), intraperitoneal, 4 weeks
PubMed · 42542926Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
J Clin Med · ex vivo human internal mammary artery rings from elective CABG surgery; n=12 segments, endothelium-intact and denuded, with and without L-NAME
PubMed · 42123221Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
Sci Rep · rat hind-limb ischemia-reperfusion by abdominal aortic clamping (45 min ischemia, 2 h reperfusion); 24 male Wistar albino rats in 4 groups of 6
PubMed · 42204242Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes
Preprints.org · preprint, not peer reviewed; retrospective cohort built from de-identified clinical notes in a U.S. federated health-records network, 1,039 patients with documented BPC-157 use, 2020-2026, curated by a large language model with physician validation
Se kildeSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Sports Med · narrative review covering AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin, Tb4 and TB-500
PubMed · 41966639KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARgamma signaling
Tissue Cell · MDI-induced adipocyte differentiation in 3T3-L1 preadipocytes
PubMed · 42585803
Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning.